Search Results for: covid-19
Articles
IMUNON Announces Results From its End-of-Phase 2 Meeting With the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer November 25, 2024
IMUNON, Inc. recently announced the outcome of its recent End-of-Phase 2 in-person meeting with the US FDA, supporting the advancement...HCW Biologics & WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate November 18, 2024
HCW Biologics Inc. and WY Biotech Co., Ltd. recently announced they have entered into a worldwide exclusive license agreement to...Naobios & Sumagen Successfully Optimize HIV Vaccine Candidate for Industrial Production October 29, 2024
Naobios and Sumagen Canada Inc. recently announced the production of the HIV-1 vaccine candidate at bench scale. This key milestone...mRNA Licensing Agreements Surge 800% in Value as Confidence Grows Beyond Vaccines October 16, 2024
Messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals saw a staggering 800% increase in licensing agreement deal values from 2019 to 2024YTD,...Sterling Pharma Solutions Announces Partnership With Soligenix October 3, 2024
Sterling Pharma Solutions and Soligenix recently announced a partnership that will see Sterling manufacture a GMP-quality synthetic hypericin developed by...FORMULATION FORUM - Lyophilization Technology - An Enabler for Stable Formulations of Small & Large Molecules October 2, 2024
Shaukat Ali, PhD, and Jim Huang, PhD, explain how lyophilization or freeze-drying technology is one of the ideal methods that leads to immobilization of drug and other components that remain in solid or powder state for extended periods without concerns of degradation, and how it has also been applied to improve drug solubility by means of amorphous solid dispersions.
EXECUTIVE INTERVIEW - Respiratory Drug Development: Lonza Experts Share Trends & Key Takeaways October 1, 2024
Beatriz Fernandes, Principal Scientist for R&D, and Kim Shepard, Director, Technology Head Respiratory Delivery, at Lonza, discuss their presentations at RDD 2024, current trends, and the future of the inhalation space.
FORMULATION DEVELOPMENT - Practical & Purposeful: Creating Novel Compounds Via Rediscovery R&D & Cannabinoid Molecules October 1, 2024
Mark Bleackley, PhD, says as time goes on, more companies will discover the benefits of drug repurposing – and how to successfully use such strategies to develop new, patentable drug products. In fact, repurposing could be exactly what’s needed to enable pharmaceutical and biotechnology companies to more swiftly develop treatments for indications with significant unmet medical needs.
Recipharm & Exela Announce Exclusive Strategic Alliance October 1, 2024
Recipharm and Exela Pharma Sciences recently announced their exclusive strategic alliance aimed at enhancing sterile manufacturing capabilities in the US....SPECIAL FEATURE - Injection Devices: From Pens & Autoinjectors to Pills, Sprays & Capsules, Injections Become More Efficient September 6, 2024
Contributor Cindy H. Dubin reports on innovative and promising injection technologies that are ever more user friendly, versatile, precise, and life-saving.
DRUG DELIVERY - Viewing Lipid Nanoparticle Delivery Technology Through the Lens of a CRDMO September 5, 2024
Lu Tian, PhD, says the complexity of LNP formulations demands diverse and integrated capabilities for development – incorporating lipids, oligonucleotides, small molecules, and sometimes antibodies or ligands, and thus it requires a cohesive approach.
SILICON-STABILIZED HYBRID LNPS - Next-Generation Delivery of RNA Therapeutics September 5, 2024
Suzanne Saffie-Siebert, PhD, Michael Welsh, PhD, Nissim Torabi-Pour, PhD, and Flavia M. Sutera, PhD, review current shortcomings, as well as some accompanying manufacturing challenges, and will show how they can be addressed by SiSaf’s silicon-stabilized hybrid LNPs.
Pharma CMO M&A Activity Shifts Focus to Scaling in 2023 August 20, 2024
Merger and acquisition (M&A) activity in the pharmaceutical contract manufacturing industry declined in 2023 compared to 2021-22. High inflation and...Evonik Expands its Formulation Capabilities for Lipid Nanoparticles Used for mRNA & Gene Therapies August 13, 2024
Evonik is collaborating with KNAUER Wissenschaftliche Geräte GmbH, a manufacturer of scientific instruments, to improve the upscaling of lipid nanoparticle...GeoVax Announces Phase 2 Plans for Cancer Therapy Following Clinical Advisory Committee Review July 31, 2024
GeoVax Labs, Inc. recently announced the next steps for the clinical development of its Gedeptin cancer therapy, following a clinical...IMUNON Announces 11.1 Month Increase in Overall Survival in Patients With Newly Diagnosed, Advanced Ovarian Cancer Treated With IMNN-001 July 30, 2024
IMUNON, Inc. recently announced positive topline results from the Phase 2 OVATION 2 Study with IMNN-001 in patients with advanced...Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational July 11, 2024
Rentschler Biopharma SE recently announced the company’s new state-of-the-art production line, formerly known as the Rentschler Biopharma Manufacturing Center (RBMC),...CureVac Initiates Strategic Restructuring to Align Resources With Focus on High-Value mRNA Pipeline Opportunities July 3, 2024
CureVac N.V. recently announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other...API & the University of Alberta Break Ground on Canada’s Largest Manufacturing Facility for Critical Medicines June 20, 2024
Construction is set to begin on a crucial pharmaceutical manufacturing facility in the Edmonton Research Park that will provide Canadians...Truveta Announces Support for Regulatory Submissions to the FDA & Global Regulatory Authorities June 18, 2024
Truveta recently announced regulatory and audit capabilities to support its customers for real-world evidence (RWE) submissions to the US FDA...
